Teva Pharmaceutical Industries (NYSE:TEVA) Given New $40.00 Price Target at Scotiabank

Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by investment analysts at Scotiabank from $35.00 to $40.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a “sector outperform” rating on the stock. Scotiabank’s price objective would suggest a potential upside of 21.59% from the stock’s current price.

Several other equities research analysts have also commented on TEVA. Wall Street Zen lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Sunday, January 18th. The Goldman Sachs Group lifted their price target on Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the company a “buy” rating in a report on Friday, December 19th. Barclays initiated coverage on Teva Pharmaceutical Industries in a research note on Tuesday, December 9th. They set an “overweight” rating and a $35.00 price objective for the company. Jefferies Financial Group lifted their target price on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $35.67.

Teva Pharmaceutical Industries Trading Down 0.9%

TEVA traded down $0.31 during trading on Thursday, hitting $32.90. 3,028,422 shares of the stock were exchanged, compared to its average volume of 10,375,811. The company has a debt-to-equity ratio of 2.31, a quick ratio of 0.82 and a current ratio of 1.11. The firm has a 50 day simple moving average of $30.12 and a 200 day simple moving average of $22.96. The firm has a market cap of $37.73 billion, a price-to-earnings ratio of 54.91, a P/E/G ratio of 1.85 and a beta of 0.66. Teva Pharmaceutical Industries has a 1 year low of $12.47 and a 1 year high of $33.43.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. The business had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.13% and a net margin of 4.24%.The business’s revenue was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, equities analysts expect that Teva Pharmaceutical Industries will post 2.5 EPS for the current year.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 216,892 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the completion of the sale, the insider owned 52,828 shares of the company’s stock, valued at approximately $1,517,748.44. The trade was a 80.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Richard Daniell sold 115,468 shares of the stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $28.68, for a total value of $3,311,622.24. Following the completion of the transaction, the vice president directly owned 48,384 shares in the company, valued at $1,387,653.12. This represents a 70.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 622,060 shares of company stock worth $17,076,965. Corporate insiders own 0.55% of the company’s stock.

Institutional Trading of Teva Pharmaceutical Industries

A number of hedge funds have recently modified their holdings of the stock. Grove Bank & Trust raised its position in Teva Pharmaceutical Industries by 300.0% during the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after acquiring an additional 750 shares in the last quarter. Advisors Asset Management Inc. purchased a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at approximately $41,000. Cromwell Holdings LLC lifted its stake in shares of Teva Pharmaceutical Industries by 40.3% in the 3rd quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock valued at $44,000 after purchasing an additional 629 shares during the period. Sound Income Strategies LLC lifted its stake in shares of Teva Pharmaceutical Industries by 3,715.8% in the 2nd quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock valued at $49,000 after purchasing an additional 2,824 shares during the period. Finally, MAI Capital Management boosted its holdings in Teva Pharmaceutical Industries by 26.8% during the second quarter. MAI Capital Management now owns 3,293 shares of the company’s stock worth $55,000 after buying an additional 697 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries News Summary

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q4 results beat expectations: Teva reported $0.96 EPS vs. $0.65 consensus and revenue of $4.71B vs. $4.36B est., driven by branded-drug sales and margin improvements — a clear near-term earnings beat. Earnings Press Release
• Positive Sentiment: Pipeline / milestone upside: Management disclosed a milestone payment tied to starting a late?stage study for ulcerative colitis and Crohn’s disease, highlighting potential future revenue streams beyond generics. Reuters: Q4 profit, revenue rise
• Positive Sentiment: Full-year momentum: Teva reported 2025 revenues of ~$17.3B (up ~4% YoY) and management framed the business as executing a “pivot-to-growth” with a strengthening innovative portfolio. This supports a multi-year growth narrative. Globe Newswire: Full-year summary
• Neutral Sentiment: Earnings call and slide deck: Management’s Q&A and the presentation provide detail on product mix, pricing, and pipeline timing — useful for modeling upside but not changing the immediate story. (Call transcript & slides available.) Earnings Call Transcript Earnings Presentation
• Neutral Sentiment: Marketing / awareness initiatives: Teva launched patient-awareness content around Huntington’s disease (celebrity partnership) — positive for reputation and long-term patient engagement but unlikely to move near-term earnings. Yahoo Finance: Will Forte campaign
• Negative Sentiment: Guidance disappointed on revenue: FY?2026 EPS guidance was set at $2.57–$2.77 (roughly in line with consensus) but revenue guidance of $16.4–$16.8B came in below the ~$17.0B street estimate — a growth/visibility miss that likely pressured the stock. Guidance / Press Release

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.